<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216111</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan TNBC Adjuvant CT</org_study_id>
    <nct_id>NCT01216111</nct_id>
  </id_info>
  <brief_title>Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)</brief_title>
  <official_title>A Prospective， Randomized， Open-label， Multicentric，phaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Anti-Cancer Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies in Western country show that triple-negative breast cancer has aggressive&#xD;
      clinical and pathological features compared with non-triple negative breast cancer, including&#xD;
      onset at a young age, advanced clinical stage, high histologic and nuclear grade and more&#xD;
      distant recurrence.&#xD;
&#xD;
      According to the characteristics of triple negative breast tumor, the TNBC patients can&#xD;
      benefit neither from hormonal therapies nor from target therapies against Her2 receptors. The&#xD;
      only systemic therapy currently available is chemotherapy, and prognosis remains poor. It&#xD;
      becomes more and more important to investigate the sensitive chemotherapy regimen for triple&#xD;
      negative patients.&#xD;
&#xD;
      Cisplatin-based regimen was active for the patients of lung cancer, colorectal cancer and&#xD;
      ect. Triple negative breast cancer patients were more sensitive to platinum-based&#xD;
      chemotherapy regimens according to the results of some retrospective studies.&#xD;
&#xD;
      The investigators hypothesized that paclitaxel combined with cisplatin is more sensitive to&#xD;
      triple negative breast cancer compared with CEF followed by docetaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility Female adults(18-70 years old) are eligible if they had histologically confirmed&#xD;
      primary breast cancer. Patients also had Eastern Cooperative Oncology Group(ECOG) Performance&#xD;
      status of 0 or 1, absolute neutrophil count (ANC)&gt;1500/mm3,hemoglobin &gt;90g/dL, and platelet&#xD;
      count &gt;100,000/mm3,creatinine&lt;2.5 times the upper limit of normal(ULN)）, transaminases&lt;3&#xD;
      times ULN or alkaline phosphatase&lt;4 times ULN if transaminases was normal, and total&#xD;
      bilirubin &lt;1.5 times ULN. Exclusion criteria were active infection, pregnancy, other primary&#xD;
      malignancy (except in situ carcinoma of cervix or adequately treated nonmelanomatous&#xD;
      carcinoma of the skin), any documented distant metastasis and uncontrolled systemic diseases.&#xD;
&#xD;
      This study protocol was approved by institutional ethic review boards and conducted according&#xD;
      to guidelines for good clinical practice and the Helsinki Declaration.All patients provided&#xD;
      written informed consent.&#xD;
&#xD;
      Outcome Measures Primary Endpoint：5 year Disease Free Survival（DFS） Second Endpoints：5 year&#xD;
      distant disease free survival （DDFS） 5 year event free survival （EFS） 5 year overall survival&#xD;
      （OS） 5 year DFS in gBRCA1 mutation carriers and homologous recombination repair (HRR)-related&#xD;
      gene mutation carriers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Actual">April 20, 2016</completion_date>
  <primary_completion_date type="Actual">April 20, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 year</time_frame>
    <description>time from random assignment to first relapse (local, regional and distant), contralateral breast cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>distant disease-free survival</measure>
    <time_frame>5 year</time_frame>
    <description>time from random assignment to distant recurrence or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse-free survival</measure>
    <time_frame>5 year</time_frame>
    <description>time from the date of randomization to local, regional, distant relapse or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival gBRCA1 mutation carriers and homologous recombination repair (HRR)-related gene mutation carriers</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>time from randomization until death with any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">647</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>6 cycles of PC adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel 80 mg/m2 and carboplatin (area under the curve [AUC]= 2) on day 1, 8, 15 every 28 days for six cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 cycles of FEC followed by 3 cycles of Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel Cisplatin</intervention_name>
    <description>Paclitaxel 80 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15&#xD;
1 cycle = 28days&#xD;
PC*6</description>
    <arm_group_label>6 cycles of PC adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)</intervention_name>
    <description>fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously</description>
    <arm_group_label>3 cycles of FEC followed by 3 cycles of Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women aged from 18 to 70 years;&#xD;
&#xD;
          2. Histologically proven invasive unilateral breast cancer (regardless of the type);&#xD;
&#xD;
          3. Initial clinical condition compatible with complete initial resection;&#xD;
&#xD;
          4. No residual macro or microscopic tumor after surgical excision;&#xD;
&#xD;
          5. Beginning of chemotherapeutic treatment no later than day 42 after the initial&#xD;
             surgery;&#xD;
&#xD;
          6. positive lymph node or negative lymph node with tumor size &gt; 1.0cm&#xD;
&#xD;
          7. Patient presenting one of the following criteria (reviewed before randomization by&#xD;
             referent pathologist):&#xD;
&#xD;
             Triple negative （ER-PR-Her-2-） Hormone receptor negativity is defined as ER&lt;1%, PR&lt;1%&#xD;
             (IHC), HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH negative].&#xD;
&#xD;
          8. No clinically or radiologically detectable metastases (M0);&#xD;
&#xD;
          9. No peripheral neuropathy &gt; 1;&#xD;
&#xD;
         10. WHO Performance status (ECOG) of 0 or 1;&#xD;
&#xD;
         11. Adequate recovery from recent surgery (at least one week must have elapsed from the&#xD;
             time of a minor surgery (excluding breast biopsy); at least three weeks for major&#xD;
             surgery);&#xD;
&#xD;
         12. Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x&#xD;
             109/l, Hemoglobin &gt; 9 g/dl);&#xD;
&#xD;
         13. Adequate hepatic function: ASAT and ALAT ≤ 3 ULN alkaline phosphatases ≤ 2.5 ULN,total&#xD;
             bilirubin ≤ 1,5 ULN;&#xD;
&#xD;
         14. Adequate renal function: serum creatinine ≤ 1 ULN;&#xD;
&#xD;
         15. Patients accepting contraception intake during the overall length of treatment if of&#xD;
             childbearing potential;&#xD;
&#xD;
         16. Adequate cardiac function, LEVF value &gt; 50% by Muga scan or echocardiography;&#xD;
&#xD;
         17. Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Bilateral breast cancer or patient with controlateral DCIS;&#xD;
&#xD;
          2. Any metastatic impairment, including homolateral sub-clavicular node&#xD;
             involvement,regardless of its type;&#xD;
&#xD;
          3. Any T4 lesion (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast&#xD;
             cancer);&#xD;
&#xD;
          4. ER+ or PR+ or Her-2 overexpression&#xD;
&#xD;
          5. Any clinically or radiologically suspect and non-explored damage to the controlateral&#xD;
             breast;&#xD;
&#xD;
          6. Any chemotherapy, hormonal therapy or radiotherapy before surgery;&#xD;
&#xD;
          7. Previous cancer (excepted cutaneous baso-cellular epithelioma or uterin peripheral&#xD;
             ephitelioma) in the preceding 5 years, including invasive controlateral breast cancer;&#xD;
&#xD;
          8. Patients already included in another therapeutic trial involving an experimental drug;&#xD;
&#xD;
          9. Patients with other concurrent severe and/or uncontrolled medical disease or infection&#xD;
             which could compromise participation in the study;&#xD;
&#xD;
         10. LEVF &lt; 50% (MUGA scan or echocardiography);&#xD;
&#xD;
         11. Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart&#xD;
             failure, uncontrolled hypertension (&gt;150/90), myocardial infarction or cerebral&#xD;
             vascular accidents) within 6 months prior to randomization;&#xD;
&#xD;
         12. Known prior severe hypersensitivity reactions to agents containing Cremophor EL;&#xD;
&#xD;
         13. Women of childbearing potential who are unwilling or unable to use an acceptable&#xD;
             method to avoid pregnancy for the entire study period and up to 8 weeks after&#xD;
             treatment completion;&#xD;
&#xD;
         14. Women who are pregnant or breastfeeding. Adequate birth control measures should be&#xD;
             taken during study treatment phase;&#xD;
&#xD;
         15. Women with a positive pregnancy test en enrollment or prior to study drug&#xD;
             administration;&#xD;
&#xD;
         16. Patients with any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial;&#xD;
&#xD;
         17. Individual deprived of liberty or placed under the authority of a tutor.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52.</citation>
    <PMID>10963602</PMID>
  </reference>
  <reference>
    <citation>Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007 Apr 15;13(8):2329-34.</citation>
    <PMID>17438091</PMID>
  </reference>
  <reference>
    <citation>Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 2006 Nov;12(11):537-44. Epub 2006 Sep 29. Review.</citation>
    <PMID>17011236</PMID>
  </reference>
  <reference>
    <citation>Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008 Jan;52(1):108-18. doi: 10.1111/j.1365-2559.2007.02889.x. Review.</citation>
    <PMID>18171422</PMID>
  </reference>
  <reference>
    <citation>Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007 Mar;8(3):235-44. Review.</citation>
    <PMID>17329194</PMID>
  </reference>
  <reference>
    <citation>Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.</citation>
    <PMID>17671126</PMID>
  </reference>
  <reference>
    <citation>Hayes DF, Ethier S, Lippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat. 2006 Nov;100(2):237-8. Epub 2006 Jun 14.</citation>
    <PMID>16773436</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>May 17, 2020</last_update_submitted>
  <last_update_submitted_qc>May 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>triple negative breast cancer，local recurrence,distant metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

